WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome

Acta Haematologica

Volumn 112, Issue 1-2, 2004, Pages 79-84

  Cilloni, Daniela ^a   Saglio, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Acute leukemia; Minimal residual disease; WT1

Indexed keywords

GENE PRODUCT; IMMUNOGLOBULIN RECEPTOR; MOLECULAR MARKER; PROTEIN WT1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

CELL TRANSFORMATION; FUSION GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA CELL; MARKER GENE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEPHROBLASTOMA; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; HUMANS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; NEOPLASM, RESIDUAL; RNA, NEOPLASM; WT1 PROTEINS;

EID: 2642518589     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077562     Document Type: Review

References (36)

1. Fearon ER, Volgelstein B, Feinberg AP: Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumours. Nature 1984;309:176-178.
2. Koufos A, Hansen MF, Lampkin BC, Workman ML, Copeland NG, Jenkins NA, Cavenee WK: Loss of alleles on human chromosome 11 during genesis of Wilms' tumor. Nature 1984;309:170-172.
3. Miller RW, Fraumeni JF, Manning MD: Association of Wilms' tumor with aniridia, hemihypertrophy and other congenital anomalies. N Engl J Med 1964;270:922-927.
4. Call KM, Glaser T, Ito CY, Buckler A, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-520.
5. Cook DM, Hinkes MT, Bernfield M, Rauscher FJ 3rd: Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 1996;13:1789-1799.
6. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR, Haber DA: WT1 suppress synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14:4662-4675.
7. Hewitt SM, Hamada S, McDonnell TJ Rauscher FJ 3rd, Saunders GF: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 1995;55:5386-5389.
8. Hosono S, Gross I, English MA, Haira KM, Fearon ER, Licht JD: E-cadherin is a WT1 target gene. J Biol Chem 2000;275:10943-10953.
9. Lee SB, Huang K, Palmer R, Troung VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA: The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 1999;98:663-673.
10. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Schpman R, Rheinwald J, Demetri G: The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993;4:415-420.
11. Little M, Holmes G, Walsh P: WT1:What has the last decade told us? Bioessay 1999;21:191-202.
12. Pritchard-Jones K, Fleming S: Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumour: Implications for tumour histogenesis. Oncogene 1991;6:2211-2220.
13. Baird PM, Simmons PJ: Expression of the Wilms tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997;25:312-320.
14. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L: The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997;25:945-950.
15. Menssen HD, Renkl HJ, Entezami M, Thiel E: Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997;89:3486-3487.
16. Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A: Downregulation of the Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood 1994;83:1876-1882.
17. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Nutter M, Schwartz S, Reinhardt R, Thiel E: Presence of Wilms' tumor gene (WT1) transcripts and WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-1067.
18. Miwa H, Beran M, Saunders GF: Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-409.
19. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ: A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 1996;12:1005-1014.
20. Deuel TF, Guan LS, Wang ZY: Wilms' tumor gene product WT1 arrests macrophage differentiation of HL60 cells through its zinc-finger domain. Biochem Biophys Res Commun 1999;254:192-196.
21. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Kishimoto T, Sugiyama H: Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405-1412.
22. Smith SI, Weil D, Johnson GR, Boyd AW, Li CL: Expression of the Wilms' tumor suppressor gene, WT1 is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. Blood 1998;91:764-773.
23. Svedberg H, Chylicki K, Baldetorp B, Rauscher FL 3rd, Gullberg U: Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks part of the differentiation program. Oncogene 1998;16:925-932.
24. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA: The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitors cells. EMBO J 2001;20:1897-1909.
25. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, Rege-Cambrin G, Guerrasio A, Divona M, Lo Coco F, Saglio G: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-2121.
26. Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Halhs P, Tisljar K, Prigljnger S, Mitterbauer M, Novak M, Mitterbauer G, Mannhalter C, Haas OA, Lechner K, Jäger U: Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12:1886-1894.
27. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Akiyama T, Kischimoto T, Sugiyama H: Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998;91:2969-2976.
28. Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L: Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997;90:4230-4232.
29. Menssen HD, Siehl JM, Thiel E: Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol 2002;76:103-109.
30. Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J, Sedlacek P, Vavra V, Michalova K, Jarosova M, Stary J: Real time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002;16:1381-1389.
31. Cilloni D, Messa F, Gottardi E, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G: Very significant correlation between WT1 expression level and the IPSS score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21:1988-1995.
32. Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, Le Coutre P, Schmidt CA: Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: Implications for monitoring human leukemias. Br J Haematol 2001;114:313-318.
33. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Fuchigami K, Tomonaga M, Toyama K, Aozasa K, Kishimoto T, Sugiyama H: The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999;13:393-399.
34. Schmid D, Heinze G, Linnerth B: Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-643.
35. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, Oji Y, Tamaki H, Kyo T, Dohy H, Hiraoka A, Masaoka T, Koshimoto T, Sugiyama H: Log-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88:2267-2278.
36. Ogawa H, Tamaki H, Ikegame K Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami H, Fujioka T, Masuda T, Taniguchi Y, Nischida S, Oji Y, Oka J, Sugiyama H: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-1704.